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Movement disorders reveal Creutzfeldt-Jakob disease
Abstract
Human prion diseases are sometimes difficult to diagnose because few clinical features distinguish them
reliably from other neurological disorders. A new study suggests that analysis of movement disorders
might contribute to the clinical differentiation of sporadic Creutzfeldt-Jakob disease from Alzheimer
disease and dementia with Lewy bodies.
Movement disorders in Creutzfeldt-Jakob disease 
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Human prion diseases are characterized by progressive cognitive dysfunction and a 
spectrum of associated neurological disturbances, e.g., of the motor system, none of 
which are specific. Edler and colleagues1 reviewed the motor system abnormalities in a 
large collective of patients suspected of having Creutzfeldt-Jakob disease. Ataxia and 
absence of hypokinesia were identified as distinguishing features from Alzheimer`s or 
diffuse Lewy body disease. Hence the analysis of movement disorders may contribute to 
the reliable clinical differentiation between these diseases.   
 
 
Main text 
 
Prions are “proteinaceous infectious particles” that cause a group of neurological diseases 
affecting humans and various animals, and that can transduce disease to others iatrogenically 
or to experimental animals by various routes of inoculation2. All human prion diseases, 
including Creutzfeldt-Jakob disease (CJD), are defined by progressive cognitive dysfunction 
resulting in dementia. In addition, most patients suffer from a spectrum of neurological 
disturbances including symptoms and signs of the motor system - such as myoclonic jerks and 
ataxia.  
 
Compared to the most important differential diagnoses - such as Alzheimer`s disease and 
diffuse Lewy body disease - prion diseases are rare. Their incidence is in the range of 1-2 per 
1,000,000/year3, 4. Nevertheless, the awareness of prion disease in the community has 
dramatically increased since bovine spongiform encephalopathy (BSE) was found to cause 
variant CJD5 which in turn can propagate iatrogenically between humans6.  
 
Despite significant progress in understanding prion pathogenesis, it has remained difficult to 
unequivocally establish the diagnosis of CJD at life-time (Box 1). The classical clinical triad 
of dementia, ataxia, and myoclonus is highly characteristic but of limited specificity. 
Diagnosis can be supported by typical EEG pattern referred to as triphasic complexes, by the 
leakage of neuronal proteins, such as neuron-specific enolase and 14-3-3 protein, from injured 
neurons into the CSF. Another intriguing surrogate marker is α1-antichymotrypsin (serpin 
3N), whose elevation can be detected both in brain tissue and in the urine of prion-infected 
organisms7. Because of the limited specificity intrinsic to all surrogate markers, the diagnosis 
is frequently only confirmed at autopsy. Familial prion diseases are a notable exception, since 
they are invariably associated with PRNP mutations and can be easily diagnosed by 
sequencing, yet most prion diseases occur sporadically and familial forms make for <10% of 
all cases. All prion diseases involve highly ordered protein aggregates containing the 
pathological PrPSc protein, and there is some hope that PrPSc detection in body fluids may 
facilitate early diagnosis8.  
 
To determine the differential diagnostic value of motor disturbances in the clinical diagnosis 
of human prion disease, Edler and colleagues1 analyzed the clinical presentation of 143 
patients referred to the German Surveillance Unit for Spongiform Encephalopathies in 
Göttingen for the assessment of possible prion disease. Given the rarity of prion affections, 
this is indeed a very large collective. Among these patients, 100 were confirmed to have 
Creutzfeldt-Jakob disease, 29 had Alzheimer’s disease (AD), 7 had diffuse Lewy body (DLB) 
disease, and 7 received other diagnoses.1 The most common motor disturbances in CJD 
patients were gait disorders (80%), myoclonus (80%) and cerebellar ataxia (77%). Ataxia and 
dysmetria along with the absence of hypokinesia suggested Creutzfeldt-Jakob disease rather 
than AD or DLB disease. Instead, pyramidal tract signs were associated with AD or DLB 
disease.  
 
A very common polymorphic site at codon 129 of the PRNP gene encodes either methionine 
or valine, and the allelic state of CJD patients modulates their clinical phenotype. Among the 
100 patients with Creutzfeldt-Jakob disease, ataxia and cogwheel rigidity were found to be 
associated with valine homozygosity whereas akinesia, was associated with methionine 
homozygosity. 
 
The authors are to be commended for an extensive analysis of clinical features of sporadic 
Creutzfeldt-Jakob disease. Importantly, the patient groups with Alzheimer`s or diffuse Lewy 
body disease were by no means representative of the phenotypes typical for these diseases – 
instead, they represented subsets of patients suspected of suffering from Creutzfeldt-Jakob 
disease by the referring physicians. Therefore, the most informative results of Edler’s study 
are those that characterize the clinical phenotype of Creutzfeldt-Jakob disease and pit it 
against atypical forms of AD and DLB dementia. We are not surprised to read that the motor 
phenotypes were modulated by the polymorphism at codon 129 of the PRNP gene, since this 
important switch controls many other aspects of prion diseases including susceptibility to 
infection and, in familial cases, even specifies CJD versus fatal familial insomnia9. This 
observation provides an interesting paradigm to study the impact of a distinct molecular 
feature on the complex manifestations of a disease phenotype. It may be of interest, in a future 
study, to correlate the clinical phenotypes not only to the genetic PRNP status but also to the 
biophysical characteristics of PrPSc aggregates – which can be ascertained, for example, by 
polythiophene fluorescence spectroscopy10. 
 
As to the diagnosis of human prion disease, a better characterization of the clinical phenotype 
is certainly welcome. The underlying unmet medical need, however, is the necessity to 
develop reliable and sensitive diagnostic procedures to confirm the diagnosis of human prion 
diseases intra vitam at the earliest possible stages of the disease. Because of their 
accessibility, this goal should be best attained by analyzing body fluids for PrPSc aggregates11 
or for prion seeds12. The urgency of this quest stems not only from the enormous 
psychological implications of a tentative diagnosis of prion disease, but also because of the 
incipient development of therapeutics that specifically target prions versus other types of 
dementing illnesses13. 
 
 
------------------------------------------------------------------------- 
Box 1 
 
Clinical and laboratory features of Creutzfeldt-Jakob disease 
• Progressive dementia 
• Myoclonus 
• Ataxia and other motor disorders 
• Triphasic complexes (EEG) 
• Elevated 14-3-3 protein in the CSF 
• PrPSc in tonsil biopsies (only for variant CJD) 
• PRNP sequence (only for familial CJD) 
 
Important differential diagnoses of Creutzfeldt-Jakob disease 
• Alzheimer`s disease 
• Diffuse Lewy body disease 
• Rapid-onset dementing disorders 
-------------------------------------------------------------------------- 
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